fashion -WSS

fashion

author：hotspot 2025-09-28 23:44:37 - browse：8322

A DNA helix, with dollar banknotes covering its strands, collapses next to another DNA helix with dollar banknotes strands — coverage from STAT — Adobe

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new form of genome editing.

Prime and Myeloid Therapeutics, a startup co-founded by Pulitzer Prize-winning writer and cancer biologist Siddhartha Mukherjee, have filed competing arbitration claims over a deal they signed in March 2022.

Prime, spun out of the lab of Broad Institute biochemist David Liu, was built on technology for making small insertions, deletions, and single-letter changes in DNA. In theory, prime editing allows researchers to tackle the vast majority of disease-causing mutations, and the first treatments are already being readied for clinical trials. But it’s a poor fit in cases where hundreds or even thousands of different mutations in a long gene cause the same diseases, such as cystic fibrosis or Duchenne muscular dystrophy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： FDA warns medical device makers about rise in fabricated data

WSS

WuXi out of biotech trade group, U.S. and China relations to blame

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Ebola: Gilead Sciences antiviral shows promise as new treatment

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Researchers tackle phage therapy hurdles for wider adoption

Wikipedia

fashion

focus

New air purifier tech could be key to improving indoor air quality

John Green on his newest strategy for fighting tuberculosis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Steward Health Care Massachusetts hospitals face fiscal disaster

BioMarin wins approval for gene therapy to treat hemophilia A

EPA limits use of carcinogenic gas for sterilizing medical devices

Hollywood unions extend contract negotiations for actors

Pushing for an NIH office for post

BioMarin wins approval for gene therapy to treat hemophilia A

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

knowledge

Pushing for an NIH office for post

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Reporting on presidential health from Reagan to Trump and Biden

entertainment

leisure time

Wikipedia

hotspot